AIM ImmunoTech Issues Letter to Stockholders
Year marked by noteworthy operational execution and clinical development progress across pipeline Company reiterates commitment to continued communication and activity...
DNA
IRADIMED CORPORATION To Present at the 35th Annual Roth Conference
WINTER SPRINGS, Fla., March 06, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced that Roger Susi,...
binx health and Birmingham AIDS Outreach Launch New Program to Improve Access to HIV and STI Testing Amid Surging Infection Rates
Sassy Little Box Program Powered by binx everywhere Digital Platform & Logistics Makes At-Home Self-Collection Kits Available Through Community Partners...
Telesis Bio to Present at the Cowen 43rd Annual Healthcare Conference
SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic...
IMUNON and Break Through Cancer Commence Enrollment in a Phase 1/2 Clinical Study of IMNN-001 in Combination with Avastin in Advanced Ovarian Cancer
The study will be partially funded by Break Through Cancer through the Ovarian Minimal Residual Disease Team Lab LAWRENCEVILLE, NJ...
CRISPR Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference
ZUG, Switzerland and BOSTON, Feb. 27, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative...
Janssen Receives Positive CHMP Opinion for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) Plus Prednisone or Prednisolone for the Treatment of Adult Patients with BRCA1/2 Gene-Mutated Metastatic Castration Resistant Prostate Cancer
If approved, niraparib in combination with abiraterone acetate (AA), will be the first dual action tablet (DAT) available in the European...
Global SCENESSE® demand drives increased CLINUVEL revenues, earnings
CLINUVEL Financial Performance CLINUVEL Group financial performance for the half year ended 30 December, since first commercial sales.MELBOURNE, Australia, Feb....
Generation Bio Outlines 2023 Strategic Priorities and Reports Fourth Quarter and Full Year 2022 Financial Results
— Company expects to announce data for Factor VIII expression in non-human primates in 2023 — Strong cash balance of...
Codexis Reports Fourth Quarter and Fiscal Year 2022 Financial Results
Biotherapeutics Application of CodeEvolver® Validated by Recent Data Supporting the Potential for Three Upcoming Investigational New Drug Applications Cash Runway...
Plus Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
Initiated ReSPECT-GBM Phase 2 and ReSPECT- LM Phase 1 trials for CNS cancers Awarded $17.6 million Cancer Prevention & Research...
Codexis and Nestlé Health Science Announce Interim Results from Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency
Interim Data from Phase 1 Proof-of-Concept Arm Indicates CDX-7108 Improves Lipid AbsorptionREDWOOD CITY, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) --...
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
– Transformational year ahead with critical Phase 2 readouts expected for programs in hepatitis B, hepatitis D and influenza with...
Graduate program in population and health systems management receives award for innovation in education
First-of-its-kind collaboration between Boise State, a leading public university and HFMA, a major professional association, is recognized by the Commission...
uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)
~ Data follow the historic approval of the first gene therapy for hemophilia B, which has been shown in clinical...
Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P. Johnson Lecture at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)
Event theme, “MS: Going Viral” touches on the role of viruses in MS, particularly Epstein-Barr, a topic related to Company’s...
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress
Initiated the global Phase 2 study of NTLA-2002, a CRISPR-based, potential single-dose treatment for hereditary angioedema (HAE)Submitted IND application for...
Omega Therapeutics Announces $40 Million Registered Direct Offering of Common Stock
CAMBRIDGE, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the...
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 1, 2023
BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
New Analyses of Sotagliflozin to Be Presented at the American College of Cardiology’s 72nd Annual Scientific Session Together With World Heart Federation’s World Congress of Cardiology
Featured presentation on the time to clinical benefit of sotagliflozin in people with worsening heart failureTHE WOODLANDS, Texas, Feb. 20,...